An observational study in Multiple Sclerosis, sponsored by Centre Hospitalier Universitaire de Nīmes. Active, not recruiting at 28 sites in 2 countries. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes — 1 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Centre Hospitalier Universitaire de Nīmes.
Among the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, this one is one of 3 that started in 2019, is one of 7 observational ones, and was the 7th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →1 of the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+ · Women only
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 15 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,150 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 81 across the 6 interventional studies, 200 across the 7 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
2 of the studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04860947Centre Hospitalier Universitaire de NīmesAssessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients | 2027-03 |
| NCT03981003Centre Hospitalier Universitaire de NīmesSerum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.
In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.
The study population is composed of consecutive patients over 15 years of age, of both sexes, recruited during consultations for a CIS, RRMS or progressive MS at the Neurology department of 30 OFSEP centres and of Nîmes and Nantes University Hospitals. The patients recruited will have an EDSS score comprised between 0 - 7.0.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:
Exclusion Criteria:
Diagnostic Test: Blood sample
2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: Inclusion
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 6 months
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 12 months
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 12 months
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 18 months
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 2 years
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 3 years
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 4 years
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 5 years
GFAP level in patients with evolving disease compared to those with stable disease
pg/mL; measured by digital ELISA
Time frame: 6 years
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: Inclusion
GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 6 months
GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 3 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 4 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 5 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 6 year
GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 18 months
GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 2 years
GFAP level in patients with disease activity (relapse or MRI activity determined by the presence of at least one T1 Gad+ lesion or at least one new T2 lesion ≤ 3 months) compared to stable patients.
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
GFAP level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with progressive disease measured by Expanded Disability Status Scale (1 point until 5.5 and 0.5 point after 5.5) compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
GFAP level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
GFAP level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
GFAP level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
GFAP level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
GFAP level in patients with relapse compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
GFAP level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
GFAP level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with isolated MRI activity compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 year
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement compared to stable patients
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with stable disease (no evidence of disease activity (NEDA) and no evidence of disease progression (NEP) from 200 patients from the OFSEP-HD cohort
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in progressive MS patients with no evidence of disease progression (NEP) from the OFSEP-HD cohort with stable disease
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with disease evolution (relapse, disability progression or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with disease activity (relapse, or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with disease activity (relapse, or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with disease activity (relapse or MRI activity)
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with relapses
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with MRI activity
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with isolated MRI activity and Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 6 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 1 year
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 18 months
Serum Neurofilament Light Chain level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 2 years
Serum GFAP level in patients with isolated MRI activity without Gadolinium-enhancement
pg/mL; measured by digital ELISA
Time frame: 2 years
Level of disability
Expanded Disability Status Scale (EDSS); scale 1= no disability to 10 = death from multiple sclerosis
Time frame: Inclusion
Level of disability
Expanded Disability Status Scale (EDSS); scale 1= no disability to 10 = death from multiple sclerosis
Time frame: Relapse (measured up to 2 years)
Severity of multiple sclerosis
Multiple Sclerosis Functional Composite
Time frame: EDSS progression (measured up to 2 years)
Severity of multiple sclerosis
Multiple Sclerosis Functional Composite
Time frame: Active MRI (measured up to 2 years)
Generic health status
EuroQol 5 dimension questionnaire (EQ-5D)
Time frame: Inclusion
Generic health status
EuroQol 5 dimension questionnaire (EQ-5D)
Time frame: Relapse (measured up to 2 years)
Generic health status
EuroQol 5 dimension questionnaire (EQ-5D)
Time frame: EDSS progression (measured up to 2 years)
Generic health status
EuroQol 5 dimension questionnaire (EQ-5D)
Time frame: active MRI (measured up to 2 years)
Use of Disease Modifying Drugs
Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)
Time frame: Inclusion
Use of Disease Modifying Drugs
Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)
Time frame: 6 monrths
Use of Disease Modifying Drugs
Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)
Time frame: 1 year
Use of Disease Modifying Drugs
Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)
Time frame: 18 months
Use of Disease Modifying Drugs
Categorized by class type of treatment (1st line, 2nd line and 3rd line therapies)
Time frame: 2 years
Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
pg/mL; measured by digital ELISA
Time frame: Month 6
Serum GFAP in 800 patients from the OFSEP cohort including Multiple Sclerosis patients at different stages and Neuromyelitis optica spectrum disorder patients
pg/mL; measured by digital ELISA
Time frame: Month 6
Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
pg/mL; measured by digital ELISA
Time frame: Inclusion
Serum Neurofilament Light Chain in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
pg/mL; measured by digital ELISA
Time frame: Month 6
Serum GFAP in 400 patients from the OFSEP cohort with a Clinically Isolated Syndrome at inclusion
pg/mL; measured by digital ELISA
Time frame: Month 6
Create biobank
Blood samples
Time frame: Inclusion
Create biobank
Blood samples
Time frame: 6 months
Create biobank
Blood samples
Time frame: 1 year
Create biobank
Blood samples
Time frame: 18 months
Create biobank
Blood samples
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2019 (actual). Primary completion is estimated for Jun 2027, 97 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 97 months is above that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jun 2028 → Jun 2027 and completion Jun 2028 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →